Fibrogen INC 10-Q quarterly reports

Kyntra Bio, Inc. (KYNB) filed its Q1 2026 10-Q, detailing a net loss from continuing operations and strategic updates on its oncology and rare disease pipeline, including FG-3246 and roxadustat.

FibroGen reported significantly reduced net losses and advanced its key clinical programs for prostate cancer and anemia, following the divestiture of its China operations.

FibroGen reports reduced losses and significant cost cuts, but warns of substantial doubt about its ability to continue as a going concern without the pending $210 million China asset sale.

FibroGen reports Q1 2025 results, including an amendment to its financing agreement and the strategic decision to sell its China roxadustat assets to AstraZeneca.

FibroGen's Q3 2024 results show a 27% increase in revenue year-over-year, driven by product sales in China, while the company continues to manage costs and navigate a challenging financial landscape.

FibroGen's Q2 2024 results show a 32% increase in revenue compared to the same period last year, driven by roxadustat sales in China and a one-time adjustment.

FibroGen's first quarter 2024 results show a significant increase in revenue and a reduction in operating losses compared to the same period last year.